Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of EGFR/HER2 inhibitor combined with pyrimidine antimetabolic drug

A pyrimidine, anti-metabolism technology, applied in drug combinations, anti-tumor drugs, pharmaceutical formulations, etc., can solve the problems of unknown effects and undisclosed use of compound A combined with capecitabine in breast cancer.

Inactive Publication Date: 2021-12-10
JIANGSU HENGRUI MEDICINE CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] However, the above-mentioned literature does not disclose the use of compound A combined with capecitabine for the treatment of breast cancer, and it is not known what effect it can achieve

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of EGFR/HER2 inhibitor combined with pyrimidine antimetabolic drug
  • Application of EGFR/HER2 inhibitor combined with pyrimidine antimetabolic drug
  • Application of EGFR/HER2 inhibitor combined with pyrimidine antimetabolic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: A randomized, open-label, parallel-controlled, multicenter phase I / II clinical study of compound A combined with capecitabine versus lapatinib combined with capecitabine in the treatment of HER2-positive metastatic breast cancer (NCT02422199)

[0034] 1 Research purpose and endpoint indicators

[0035] 1.1 Research purpose

[0036] To compare the safety and efficacy of compound A combined with capecitabine regimen and lapatinib combined with capecitabine regimen in the treatment of HER2 positive metastatic breast cancer.

[0037] 1.2 Endpoint indicators

[0038] 1. The main endpoint indicators

[0039] Safety indicators: ECOG score, vital signs, physical examination, laboratory test indicators (hematuria and stool routine, blood biochemistry, pregnancy test and virological screening), ECG, echocardiography, adverse events (AE), according to NCI- CTC AE 4.0 standard.

[0040] Effectiveness indicators: The objective response rate (ORR) within 12 cycles of r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of an EGFR / HER2 inhibitor combined with a pyrimidine antimetabolic drug, in particular to application of an EGFR / HER2 receptor tyrosine kinase inhibitor combined with a pyrimidine antimetabolic drug in preparation of drugs for treating cancers.

Description

[0001] This application is a divisional application of a Chinese patent application with the application number 201880001320.5, the application date is January 19, 2018, and the invention title is "Use of EGFR / HER2 Inhibitors Combined with Pyrimidine Antimetabolites". technical field [0002] The invention relates to the use of an EGFR / HER2 receptor tyrosine kinase inhibitor combined with pyrimidine anti-metabolism drugs in the preparation of drugs for treating cancer. Background technique [0003] Receptor tyrosine kinases (RTKs) are a class of transmembrane proteins involved in growth factor signal transduction, including an extracellular domain containing a ligand binding site, a single transmembrane hydrophobic α-helical region, Contains an intracellular domain of protein tyrosine kinase (RTK) activity. The occurrence and development of many tumors are closely related to the abnormal expression of tyrosine kinases. Existing data show that more than 50% of proto-oncogene...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/4709A61K31/7068A61P35/00A61P35/04
CPCA61K45/06A61K31/4709A61K31/7068A61P35/00A61P35/04A61K2300/00A61K31/706A61K31/513A61K31/444
Inventor 邹建军曹国庆朱晓宇
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com